Form 4 for CALC CalciMedica, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001415889-24-001829 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-25 | 2024-01-23 | CALC | WILSON ROBERT N | Dir | A - Grant | $4.27 | +68.3K | 250.5K | +38% | +$291.7K |
| DM | 2024-01-25 | 2024-01-23 | CALC | WILSON ROBERT N | Dir | A - Grant | $0.13 | +68.3K | 34.2K | New | +$8,881 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | A | A | 68,314 | $4.27 | 250,475 | D | — | — | |
| 2 | Derivative | Warrant | 2024-01-23 | A | A | 34,157 | $0.13 | 34,157 | D | $5.36 · 2024-01-23 to 2024-12-31 | 34,157 Common Stock | (F2) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 3 | Derivative | Warrant | 2024-01-23 | A | A | 34,157 | $0.13 | 34,157 | D | $7.15 · 2024-01-23 to 2026-12-31 | 34,157 Common Stock | (F3) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |